IQVIA Holdings (IQV) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is IQV's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Eurizon Capital SGR S.p.A. increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 11.4% in a recent quarter, according to its most recent 13F filing with the SEC. The firm owned 54,052 shares of the medical …

IQV's growth is fueled by rising clinical research demand, strong commercial services momentum, AI adoption and operational efficiencies that boost profitability.…

CenterBook Partners LP lessened its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 74.3% in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,57…

Meta shares rose 29% after the company launched a new AI product called Muse, which is designed to make agentic AI capabilities accessible to ordinary consumers. IQVIA shares were up 39% as industry demand trends improve…

Net new clinical bookings reached $3.2 billion in the third quarter. Last 12-month net new bookings increased 14% to $11.7 billion.…

US government debt-to-GDP exceeds 120%, while annual interest payments now surpass the budget for national defense. Our three best-performing stocks this quarter were Meta, IQVIA and Shell. Our three largest detractors t…

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

Citizens Financial Group Inc. RI increased its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 67.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exch…

IQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rat…

IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.…

IQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and h…

IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.…

IQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial …

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Maia Wealth LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 44.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional …

First Citizens Bank and Trust Co. acquired a new position in shares of IQVIA Holdings Inc. (NYSE: IQV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm a…

RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif.…

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to…

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate princ…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of …

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Develop…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to…

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 10. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

